New hope for frail cancer patients: enhertu trial targets Hard-to-Treat GI cancers
NCT ID NCT07126561
First seen Jan 11, 2026 · Last updated May 19, 2026 · Updated 19 times
Summary
This study tests the drug Enhertu in 43 people with newly diagnosed, advanced HER2-positive cancer of the esophagus, stomach, or gastroesophageal junction who are too weak for standard chemotherapy. Participants receive Enhertu by IV every 3 weeks. The goal is to see how many patients' tumors shrink and to monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 POSITIVE NEWLY DIAGNOSED METASTATIC ESOPHAGEAL, GASTRIC, GEJ CANCER PATIENTS WITH AN ECOG PERFORMANCE STATUS OF 2 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.